Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Jetstar to Charge for Overhead Cabin Bags From February 
VEJLE, Denmark, March 09, 2018 -- The market leading nicotine gum manufacturer, Fertin Pharma A/S, adds another milestone in the protection of compressed nicotine gum. While Fertin Pharma A/S has already obtained a large and complex patent portfolio on compressed two-layered nicotine gum, the new patent issued by the European Patent Office is believed to strengthen the competitive landscape in the segment of one-layered compressed nicotine gum. Fertin Pharma A/S has been issued numerous patents on this technology within the past decade. Now, Fertin Pharma A/S is the nicotine manufacturer with the largest patent portfolio on compressed nicotine gum.
Vice President of BD, Marketing & Sales, Anders Dam Vestergaard, announces that Fertin Pharma A/S would enforce the patent rights against any competitor infringing the patents in the field of one-layered compressed nicotine gum. This includes the newly issued patent, EP 2 229 158 B1, and other patents relevant for one-layered compressed gum technology. “It is fairly easy to detect infringement of our patent rights, and we have a close eye on our competitors in this field of technology,” says Anders Dam Vestergaard. “In addition, we believe that our complex patent portfolio makes it difficult for our competitors to even enter this technology segment without infringing our patent rights,” Anders Dam Vestergaard adds.
Further to the newly issued European patent, Fertin Pharma A/S has been issued a number of US and Indian patents with relevance in the field of one-layered compressed nicotine technology. These include US 8,603,440, US 8,722,022, US 8,524,196 and US 8,529,875.
Fertin Pharma A/S’s main premises are located in Vejle, Denmark, with additional facilities in India. Fertin Pharma A/S is considered one of the world leading developers and manufacturers of B2B nicotine chewing gum.
For further information, please contact: Anders Dam Vestergaard Tel. +45 7215 1300 www.fertin.com
